TikoMed Ready to Initiate Clinical Studies for Amyotrophic Lateral Sclerosis (ALS), Glaucoma, Alzheimer's, Traumatic Brain Injury (TBI), Stroke and Fibroproliferative Conditions (Scarring)

VIKEN, Sweden, December 1, 2017 (Newswire.com) - The Swedish biotech company TikoMed AB has, in close collaboration with Neuregenix Ltd, a spin-out CRO from the University of Birmingham, obtained unique results in 12 different preclinical studies using the compound, ILB. The company has been recommended, based on the extensive and well-founded experimental data, to initiate studies in patients (Phase 2) for six different disease areas, which today are characterized by major suffering and large human and socio-economic costs due to the lack of effective treatments. TikoMed and the University of Birmingham have decided to start early in 2018, with two clinical studies for ALS and Glaucoma.

During the past year, the small-scale Swedish biotech company TikoMed AB, based outside Helsingborg, has been working closely with the large and well-reputed University Hospital Birmingham, Neuregenix Ltd and the University of Birmingham’s D3B (Devices, Drugs, Diagnostics and Biomarkers) early phase trials team. The main purpose of the close co-operation has been to conduct preclinical studies for multiple disease areas using TikoMed's drug, ILB. Twelve studies have been carried out and the results have exceeded all expectations. For numerous Central Nervous System (CNS) diseases where today there is only condition decelerating medicine available at best, ILB is expected to halt the disease progress and provide distinct symptomatic improvements. With positive animal data and informative in vitro studies (including DNA microarray studies), it has been possible to identify where, how and why ILB achieves these revolutionary results.

The data we have generated on ILB whilst working with TikoMed are truly unique and throughout my career, I can truly say that they are exceptional. The pleiotropic mechanism of action of ILB we have revealed indicate the utility of this drug to treat many acute and chronic degenerative conditions. We are very excited about the clinical potential for ILB, which may prove to be a game-changing treatment for many devastating diseases.

Ann Logan, Professor, CEO, Neuregenix Ltd

Professor Ann Logan, CEO Neuregenix Ltd:

“The data we have generated on ILB whilst working with TikoMed are truly unique and throughout my career, I can truly say that they are exceptional.  The pleiotropic mechanism of action of ILB we have revealed indicate the utility of this drug to treat many acute and chronic degenerative conditions. We are very excited about the clinical potential for ILB, which may prove to be a game-changing treatment for many devastating diseases.”

In view of the completed studies (including toxicology studies), the extensive documentation and the strong patent portfolio, University Hospital Birmingham, TikoMed and D3B have concluded that they are now ready to apply for the regulatory approvals required to initiate the studies in patients. It is unusual for a small biotech company to perform six clinical studies, but they are clearly motivated by the exceptional results and the critical assessment of their experts and researchers. D3B at the Institute of Translational Medicine, Birmingham have signed a "Letter of Intent" to carry out the planned clinical trials under their management.

Simon Bach, MD, Clinical Lead of D3B early phase trials team, University of Birmingham:

"We have seen the excellent initial results, generated from the collaboration between TikoMed and Neuregenix Ltd. The staff in D3B are particularly excited to contribute to this development process and we look forward to opening our first clinical studies in 2018. From what we have seen so far this may generate breakthroughs in diseases that currently have very limited or no treatment options.”

Lars Bruce, head of the Birmingham effort at TikoMed:

"Ever since I first met Professor Ann Logan and her team in Birmingham, we have had a seamless open discussion on how we can pave the way for this technology and bring it to patients. It is an honour to work with experts like Professor Logan, Mr. Bach and all the staff at University and hospitals of Birmingham, who have such a depth of knowledge in science and at the same time are humble before the total challenge of bringing a new treatment to patients with unmet needs. That can only be achieved with an organization with a great heart and dedication to the patients. We are lucky to have found such excellence!”

---

For more information, please contact TikoMed at the following email address: [email protected].

Phone number: +46 (0)707 23 84 14

---

About TikoMed:

TikoMed is a Swedish privately held biotech company founded in 2002 in Viken, outside Helsingborg. The business idea is to develop and carry a pharmaceutical portfolio through preclinical and early clinical studies to achieve a "proof of concept" and then to enter into collaboration with established Big Pharma companies in order to enable the medicine to reach patients as soon as possible. The operational activities are characterized by creativity and innovation with the main purpose of identifying untapped approaches and opportunities to subsequently direct projects towards these indications. TikoMed is focusing on numerous disease areas, but particularly on cardiovascular and neurological diseases.

Source: TikoMed AB